Contraindicated (1)bortezomib will increase the degree or result of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or moderate CYP2C19 inhibitors may well raise mavacamten systemic exposure, leading to heart failure as a consequence of systolic dysfunction.chloramphenicol will improve the level or influence of bo